Evidence map›Paper›PMID 34667209›Full record

ArticleScientific reports2021

NR4A2 expression is not altered in placentas from cases of growth restriction or preeclampsia, but is reduced in hypoxic cytotrophoblast.

Natasha de Alwis, Sally Beard, Natalie K Binder, Natasha Pritchard, Tu'uhevaha J Kaitu'u-Lino, Susan P Walker, Owen Stock, Katie M Groom, Scott Petersen, Amanda Henry and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Natasha de AlwisTherapeutics Discovery and Vascular Function in Pregnancy Group, Mercy Hospital for Women, Heidelberg, VIC, 3084, Australia.
Sally BeardTherapeutics Discovery and Vascular Function in Pregnancy Group, Mercy Hospital for Women, Heidelberg, VIC, 3084, Australia.
Natalie K BinderTherapeutics Discovery and Vascular Function in Pregnancy Group, Mercy Hospital for Women, Heidelberg, VIC, 3084, Australia.
Natasha PritchardTranslational Obstetrics Group, Mercy Hospital for Women, Heidelberg, VIC, 3084, Australia.
Tu'uhevaha J Kaitu'u-LinoTranslational Obstetrics Group, Mercy Hospital for Women, Heidelberg, VIC, 3084, Australia.
Susan P WalkerMercy Perinatal, Mercy Hospital for Women, Heidelberg, VIC, 3084, Australia.
Owen StockTranslational Obstetrics Group, Mercy Hospital for Women, Heidelberg, VIC, 3084, Australia.
Katie M GroomLiggins Institute, University of Auckland, Auckland, 1023, New Zealand.
Scott PetersenCentre for Maternal Fetal Medicine, Mater Mothers' Hospital, South Brisbane, QLD, 4101, Australia.
Amanda HenrySchool of Women's and Children's Health, UNSW Medicine, University of New South Wales, Sydney, Australia.
Joanne M SaidDepartment of Obstetrics and Gynaecology, University of Melbourne, Mercy Hospital for Women, 163 Studley Rd, Heidelberg, VIC, 3084, Australia.
Sean SeehoNorthern Clinical School, Women and Babies Research, The University of Sydney, St Leonards, NSW, 2065, Australia.
Stefan C KaneDepartment of Obstetrics and Gynaecology, University of Melbourne, Mercy Hospital for Women, 163 Studley Rd, Heidelberg, VIC, 3084, Australia.
Stephen TongTranslational Obstetrics Group, Mercy Hospital for Women, Heidelberg, VIC, 3084, Australia.
Natalie J HannanTherapeutics Discovery and Vascular Function in Pregnancy Group, Mercy Hospital for Women, Heidelberg, VIC, 3084, Australia. nhannan@unimelb.edu.au.
University of Melbourne · AUMercy Hospital for Women · AUMater Mothers' Hospital · AUUniversity of Auckland · NZUniversity of Sydney · AUUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nuclear Receptor Subfamily 4 Group A Member 2 (NR4A2) transcripts are elevated in the circulation of individuals whose pregnancies are complicated by preterm fetal growth restriction (FGR). In this paper, we show that the cases with preeclampsia (PE) have increased circulating NR4A2 transcripts compared to those with normotensive FGR. We aimed to establish whether the dysfunctional placenta mirrors the increase in NR4A2 transcripts and further, to uncover the function of placental NR4A2. NR4A2 expression was detected in preterm and term placental tissue; expressed higher at term. NR4A2 mRNA expression and protein were not altered in placentas from preterm FGR or PE pregnancies. Hypoxia (1% O

Indexed as

AdultAntioxidantsFemaleFetal Growth RetardationHumansHypoxiaInflammationMaleNuclear Receptor Subfamily 4, Group A, Member 2Oxidative StressPlacentaPlacenta DiseasesPlacenta Growth FactorPre-EclampsiaPregnancyRNA, MessengerAntioxidantsNR4A2 protein, humanNuclear Receptor Subfamily 4, Group A, Member 2Placenta Growth FactorRNA, Messenger

Identifiers

PMID34667209
PMCPMC8526588
OpenAlexW3207109421

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.